RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?

Rigel Pharmaceuticals (RIGL) is positioned as a stronger growth prospect than Amicus Therapeutics (FOLD), driven by its significantly raised 2025 revenue guidance to $270-$280 million, fueled by robust Tavalisse sales ($68.5M, up 44% YoY in H1 2025) and new product contributions. RIGL's 2025 sales and EPS are projected to increase by 57% and 415% respectively, contrasting with FOLD's more modest 18% sales growth and its heavy reliance on Galafold ($233.1M, up 11% YoY in H1 2025), which presents competitive risks. This strong performance, coupled with RIGL's 80.1% YTD stock rally and lower price-to-sales valuation, underpins its Zacks Rank #1 (Strong Buy) compared to FOLD's #3 (Hold).

Analysis

Rigel Pharmaceuticals (RIGL) is demonstrating superior growth momentum and a more favorable risk profile compared to Amicus Therapeutics (FOLD). RIGL's diversification strategy is proving effective, with its lead drug Tavalisse posting 44% year-over-year sales growth to $68.5 million in H1 2025, complemented by a 31% sales increase from its second product, Rezlidhia, and new revenue streams from Gavreto. This strong performance prompted a significant upward revision of its 2025 total revenue guidance to $270-$280 million, with consensus estimates projecting a 57% increase in sales and a 415% rise in EPS for the year. In contrast, FOLD, while seeing 11% growth in its primary drug Galafold, remains heavily dependent on this single product and faces stiff competition from established players like Sanofi in the Pompe disease market. This divergence is reflected in market performance, with RIGL shares rallying 80.1% year-to-date while FOLD's have declined 11.3%. Furthermore, RIGL trades at a more attractive valuation with a price-to-sales ratio of 2.05, less than half of FOLD's 4.51, reinforcing its position as the stronger fundamental and growth-oriented investment.

Key Decisions for Investors

• Given Rigel's strong multi-product revenue growth, significantly raised 2025 guidance, and superior analyst estimates, investors should view RIGL as a compelling growth opportunity with a clear fundamental upside.
• For Amicus Therapeutics, the heavy reliance on its lead drug Galafold and formidable competition in its newer markets present considerable risks, warranting a cautious or hold stance until its Pombiliti and Opfolda combo demonstrates significant market share gains.
• Consider a pair trade strategy, long RIGL and short FOLD, to capitalize on the diverging financial trajectories, analyst sentiment, and starkly different stock price momentum and valuation metrics between the two companies.